Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
Open accessAbstract
BACKGROUND/AIM: Although immune checkpoint inhibitors play an important role in the therapy of lung cancer, they are associated with various immune-related adverse events and predictive factors of them are unclear. In this study, we investigated predictive factors of nivolumab-induced hypothyroidism which is one of the adverse events in patients with lung cancer. PATIENTS AND METHODS: Patients with non-small-cell lung cancer who were administered nivolumab at our hospital between December 2015 and May 2016 were retrospectively enrolled. The thyroid-stimulating hormone, free triiodothyronine, free thyroxine, thyroid peroxidase (TPO) antibody, and thyroglobulin antibody levels of each patient were analyzed. RESULTS: Of the 64 patients enrolled, 5 (7.8%) developed hypothyroidism after treatment with nivolumab. The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism. CONCLUSION: TPO and thyroglobulin antibody levels at baseline may be predictive of hypothyroidism.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients who had ICPi-induced hypothyroidism had positive anti-thyroid autoantibodies in 75 to 100% of cases.
“and that patients who had ICPi-induced hypothyroidism had positive anti-thyroid autoantibodies in 75 to 100% of cases [54,55,56,57].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [55]
Positive TPOAb and/or thyroglobulin autoantibodies (TgAb) are associated with a 40 to 70% risk of hypothyroidism during immune checkpoint inhibitor (ICPi) treatment.
“Two retrospective and two prospective studies reported that positive TPOAb and/or thyroglobulin autoantibodies (TgAb) are associated with a 40 to 70% risk of hypothyroidism during treatment”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [55]
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567 · see citing works
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · see citing works
2013 ETA Guideline: Management of Subclinical Hypothyroidism
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000356507 · Cited by 877 · see citing works
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854 · see citing works
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · see citing works
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439 · see citing works
Villadolid, J. J., & Amin, A. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.06 · Cited by 413 · see citing works
Chen, T. W., Razak, A. R. A., Bedard, P. L., Siu, L. L., & Hansen, A. R. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv182 · Cited by 246 · see citing works
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244 · see citing works
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169 · see citing works
Planchard, D., Yokoi, T., McCleod, M., Fischer, J. R., Kim, Y., Ballas, M. S., Shi, K., & Soria, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.003 · Cited by 130 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
Diagnosis and Management of Subclinical Hypothyroidism in Elderly Adults: A Review of the Literature
Hennessey, J. V., & Espaillat, R. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13532 · Cited by 75 · see citing works
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer
Zhou, G., Xiong, Y., Chen, S., Xia, F., Li, Q., & Hu, J. (2016) · Medicine · doi:10.1097/md.0000000000004611 · Cited by 51 · see citing works
Nivolumab-induced thyroid dysfunction
Tanaka, R., Fujisawa, Y., Maruyama, H., Nakamura, Y., Yoshino, K., Ohtsuka, M., & Fujimoto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw036 · Cited by 47 · see citing works
Alhusseini, M., & Samantray, J. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-119528 · Cited by 41 · see citing works
Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
Valecha, G. K., Vennepureddy, A., Ibrahim, U., Safa, F. M., Samra, B., & Atallah, J. P. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1259574 · Cited by 39 · see citing works
Wang, C., Yu, X., & Wang, W. (2016) · Medicine · doi:10.1097/md.0000000000005539 · Cited by 37 · see citing works
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, E., Sgambato, A., Chiara, G. D., Casaluce, F., Losanno, T., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133289 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 546 · see citing works
Hypertension in Thyroid Disorders
Berta, E., Lengyel, I. M., Halmi, S., Zrínyi, M., Erdei, A., Harangi, M., Páll, D., Nagy, E. V., & Bodor, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00482 · Cited by 153 · see citing works
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 130 · see citing works
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
Hommes, J. W., Verheijden, R. J., Suijkerbuijk, K. P. M., & Hamann, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585311 · Cited by 127 · see citing works
Matsuoka, H., Hayashi, T., Takigami, K., Imaizumi, K., Shiroki, R., Ohmiya, N., Sugiura, K., Kawada, K., Sawaki, A., Maeda, K., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07142-3 · Cited by 81 · see citing works
Adverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 77 · see citing works
Ma, C., Hodi, F. S., Giobbie‐Hurder, A., Wang, X., Zhou, J., Zhang, A., Zhou, Y., Mao, F., Angell, T. E., Andrews, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0613 · Cited by 66 · see citing works
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 63 · see citing works
Taylor, J., Gandhi, A., Gray, E. S., & Zaenker, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991433 · Cited by 47 · see citing works
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 46 · see citing works
Zhou, Y., Xia, R., Xiao, H., Pu, D., Long, Y., Ding, Z., Liu, J., & Ma, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107296 · Cited by 41 · see citing works
Thyroid disorders induced by immune checkpoint inhibitors
Karaviti, D., Kani, E.-R., Karaviti, E., Gerontiti, E., Michalopoulou, O., Stefanaki, K., Kazakou, P., Vasileiou, V., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-03718-2 · Cited by 40 · see citing works
Ohara, N., Kobayashi, M., Ohashi, K., Ito, R., Ikeda, Y., Kawaguchi, G., Yoneoka, Y., Hasegawa, G., & Takada, T. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2002-2 · Cited by 37 · see citing works
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
Rubino, R., Marini, A., Roviello, G., Presotto, E. M., Desideri, I., Ciardetti, I., Brugia, M., Pimpinelli, N., Antonuzzo, L., Mini, E., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02750-w · Cited by 37 · see citing works
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023) · Immunological Reviews · doi:10.1111/imr.13249 · Cited by 36 · see citing works
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35 · see citing works
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33 · see citing works
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
Tzoulis, P., Corbett, R., Ponnampalam, S., Baker, E., Heaton, D., Doulgeraki, T., & Stebbing, J. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0111 · Cited by 32 · see citing works
Ponvilawan, B., Khan, A. W., Subramanian, J., & Bansal, D. (2024) · Cancers · doi:10.3390/cancers16061225 · Cited by 33 · see citing works
Pozzessere, C., Mazini, B., Omoumi, P., Jreige, M., Noirez, L., Digklia, A., Fasquelle, F., Sempoux, C. L., & Dromain, C. (2024) · Cancers · doi:10.3390/cancers16142585 · Cited by 30 · see citing works
Giommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci‐Cerinic, M., et al. (2021) · Immuno · doi:10.3390/immuno1030017 · Cited by 29 · see citing works
Music, M., Iafolla, M. A. J., Soosaipillai, A. R., Batruch, I., Prassas, I., Pintilie, M., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., et al. (2020) · F1000Research · doi:10.12688/f1000research.22715.1 · Cited by 22 · see citing works
Deligiorgi, M. V., Sagredou, S., Vakkas, L., & Trafalis, D. T. (2021) · Cancers · doi:10.3390/cancers13215277 · Cited by 22 · see citing works
Miao, Y., Quan, W., Tang, X., Shi, W., Li, Q., Li, R. J., Wang, J., Gan, J., Dong, X., Liang, H., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89376 · Cited by 21 · see citing works
Ruggeri, R. M., Spagnolo, C. C., Alibrandi, A., Silvestris, N., Cannavò, S., & Santarpía, M. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02096-2 · Cited by 17 · see citing works
Zhou, J., Xiong, H.-F., Chen, X., Zhang, Z., Zhu, L., & Wu, B. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.689 · Cited by 16 · see citing works
The Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte‐Baran, W., & Kim, S. T. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.01.004 · Cited by 16 · see citing works
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
Jaafar, J., Fernández, E., Alwan, H., & Philippé, J. (2018) · Endocrine Connections · doi:10.1530/ec-18-0079 · Cited by 15 · see citing works
Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 13 · see citing works
Zhao, P., Li, J., Yu, L., Ma, W., & Zhao, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1581057 · Cited by 11 · see citing works
Wu, K., Xia, B., Zhang, J., Li, X., Yang, S., Zhang, M., Zhu, L., Wang, B., Xu, X., Ma, S., et al. (2022) · Cancers · doi:10.3390/cancers14153568 · Cited by 10 · see citing works
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
Huo, L., Wang, C., Ding, H., Shi, X., Shan, B., Zhou, R., Liang, P., & Hou, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1190491 · Cited by 11 · see citing works
Les dysthyroïdies sous immunothérapie anti-cancéreuse
Anceau, C. C., Abeillon, J., Maillet, D., Borson‐Chazot, F., & Disse, E. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.10.005 · Cited by 9 · see citing works
Chilelli, M. G., Signorelli, C., Berrìos, J. R. G., Onorato, A., Nelli, F., Fabbri, A., Primi, F., Marrucci, E., Virtuoso, A., Schirripa, M., et al. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10076 · Cited by 7 · see citing works
Gong, W., Zheng, E., Liu, M., Han, Y., Lyu, Z., & Guo, Q. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01986-1 · Cited by 5 · see citing works
Menz, B. D., Johnson, J. L., Gillard, D. F., Chong, W., & Ward, M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019872937 · Cited by 5 · see citing works
Zhu, Q., Hu, H., OuYang, L.-Y., Yang, R., Wei, W., Huang, P., & He, X. (2025) · BMC Cancer · doi:10.1186/s12885-025-14218-5 · Cited by 3 · see citing works
Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy
van Delft, F. A., Muller, M., Langerak, R., Koffijberg, H., Retèl, V. P., van den Broek, D. A., & IJzerman, M. J. (2021) · Medical Decision Making · doi:10.1177/0272989x211002756 · Cited by 3 · see citing works
The Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte‐Baran, W., & Kim, S. T. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.01.010 · Cited by 2 · see citing works
Lamparter, D. F., Schmid, V., Mohindra, R., Karanikas, V., Kam‐Thong, T., Šćepanović, P., Duchâteau-Nguyen, G., Roller, A., Heinzmann, D., Adams, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012891 · Cited by 2 · see citing works
Lu, L., Liu, L., Fang, W., & Liu, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1611425 · Cited by 1 · see citing works
Varghese, J. M., & Best, C. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_4 · Cited by 1 · see citing works
Jheengut, Y., Liu, Y. Q., & Liu, L. X. (2019) · journal of nutritional oncology · doi:10.34175/jno201904002
Paydary, K., Farooq, M. Z., & Mangla, A. (2020) · Endocrines · doi:10.3390/endocrines1020008
(2017) · Reactions Weekly · doi:10.1007/s40278-017-38211-9
Zhou, J., Zhang, Z., & Wu, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2222674/v1
Immunotherapy-Related Hypothyroidism: Mechanisms and Management
Demir, S. Ç., & Yazıcı, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005012
Wagner, C. A., Smith, K., James, J. A., & James, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00025-4
Lomidze, K., Kikodze, N., Gordeladze, M., Charkviani, N., & Chikovani, T. (2025) · Immuno · doi:10.3390/immuno5020021
Schmid, V., Lamparter, D., Mohindra, R., Karanikas, V., Kam‐Thong, T., Šćepanović, P., Duchâteau-Nguyen, G., Roller, A., Heinzmann, D., Adams, C., et al. (2025) · medRxiv · doi:10.1101/2025.06.01.25327978
Zhou, J., Jingzhi, W., & Liu, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1875485
- Authors
- Maekura, T., Naito, M., Tahara, M., Ikegami, N., Kimura, Y., Sonobe, S., Kobayashi, T., Tsuji, T., Minomo, S., Tamiya, A., & Atagi, S.
- Affiliations
- NHO Kinki Chuo Chest Medical Center (JP)
- Venue
- In Vivo
- Published
- 2018-04-17
- Volume
- 31
- Issue
- 5
- Pages
- 1035-1039
- ISSN
- 0258-851X (ISSN-L)
- 1791-7549
- PMC
- PMC5656848
- OpenAlex
- W2750622074
- Cited by
- 51
- References
- 22
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 3 · 2017: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- In Vivo (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- nivolumab, hypothyroidism, non-small cell lung cancer, immune checkpoint inhibitors, immune-related adverse events, thyroid peroxidase antibodies, thyroglobulin antibodies, predictive factors, thyroid function
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Female, Humans, Hypothyroidism, Lung Neoplasms, Male, Middle Aged, Prognosis, Thyroid Function Tests, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
